Profound Medical Corp. (PROF)
Profound Medical Statistics
Share Statistics
Profound Medical has 30.03M shares outstanding. The number of shares has increased by 22.92% in one year.
Shares Outstanding | 30.03M |
Shares Change (YoY) | 22.92% |
Shares Change (QoQ) | 22.66% |
Owned by Institutions (%) | 55.89% |
Shares Floating | 26.63M |
Failed to Deliver (FTD) Shares | 3.75K |
FTD / Avg. Volume | 5.33% |
Short Selling Information
The latest short interest is 382.24K, so 1.27% of the outstanding shares have been sold short.
Short Interest | 382.24K |
Short % of Shares Out | 1.27% |
Short % of Float | 1.44% |
Short Ratio (days to cover) | 5.12 |
Valuation Ratios
The PE ratio is -6.68 and the forward PE ratio is -7.24. Profound Medical's PEG ratio is -0.47.
PE Ratio | -6.68 |
Forward PE | -7.24 |
PS Ratio | 17.41 |
Forward PS | 1.3 |
PB Ratio | 3.08 |
P/FCF Ratio | -7.93 |
PEG Ratio | -0.47 |
Enterprise Valuation
Profound Medical Corp. has an Enterprise Value (EV) of 161.66M.
EV / Earnings | -5.81 |
EV / Sales | 15.14 |
EV / EBITDA | -4.89 |
EV / EBIT | -4.89 |
EV / FCF | -6.89 |
Financial Position
The company has a current ratio of 10.52, with a Debt / Equity ratio of 0.08.
Current Ratio | 10.52 |
Quick Ratio | 9.64 |
Debt / Equity | 0.08 |
Total Debt / Capitalization | 7.81 |
Cash Flow / Debt | -4.58 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.46% and return on capital (ROIC) is -50.45%.
Return on Equity (ROE) | -0.46% |
Return on Assets (ROA) | -0.4% |
Return on Capital (ROIC) | -50.45% |
Revenue Per Employee | $75,211.27 |
Profits Per Employee | $-195,887.32 |
Employee Count | 142 |
Asset Turnover | 0.15 |
Inventory Turnover | 0.63 |
Taxes
Income Tax | -2K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -29.19% in the last 52 weeks. The beta is 0.77, so Profound Medical's price volatility has been higher than the market average.
Beta | 0.77 |
52-Week Price Change | -29.19% |
50-Day Moving Average | 6.8 |
200-Day Moving Average | 7.96 |
Relative Strength Index (RSI) | 31.39 |
Average Volume (20 Days) | 70.33K |
Income Statement
In the last 12 months, Profound Medical had revenue of 10.68M and earned -27.82M in profits. Earnings per share was 1.12.
Revenue | 10.68M |
Gross Profit | 7.04M |
Operating Income | -33.06M |
Net Income | -27.82M |
EBITDA | -33.06M |
EBIT | -33.06M |
Earnings Per Share (EPS) | 1.12 |
Balance Sheet
The company has 54.91M in cash and 5.12M in debt, giving a net cash position of 49.79M.
Cash & Cash Equivalents | 54.91M |
Total Debt | 5.12M |
Net Cash | 49.79M |
Retained Earnings | 0 |
Total Assets | 70.23M |
Working Capital | 62.5M |
Cash Flow
In the last 12 months, operating cash flow was -23.45M and capital expenditures 0, giving a free cash flow of -23.45M.
Operating Cash Flow | -23.45M |
Capital Expenditures | 0 |
Free Cash Flow | -23.45M |
FCF Per Share | -0.95 |
Margins
Gross margin is 65.89%, with operating and profit margins of -309.57% and -260.45%.
Gross Margin | 65.89% |
Operating Margin | -309.57% |
Pretax Margin | -260.47% |
Profit Margin | -260.45% |
EBITDA Margin | -309.57% |
EBIT Margin | -309.57% |
FCF Margin | -219.6% |
Dividends & Yields
PROF does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 18.54% |
FCF Yield | -12.92% |
Analyst Forecast
The average price target for PROF is $12, which is 98.7% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $12 |
Price Target Difference | 98.7% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Oct 16, 2019. It was a backward split with a ratio of 1:10.
Last Split Date | Oct 16, 2019 |
Split Type | backward |
Split Ratio | 1:10 |
Scores
Altman Z-Score | 6.48 |
Piotroski F-Score | 4 |